Omeros | OMER - Операционный доход





Операционный доход Изменить Дата
Adma Biologics USD 62.75M 11.74M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Immunic USD -25.73M 2.91M 2024-09
Insmed USD -249.71M 11.64M 2025-12
Knight Therapeutics CAD 6.21M 3.27M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Omeros USD -35.41M 23.75M 2024-09
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Rockwell Medical USD 515K 1.84M 2024-06
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12
Xoma USD -15.64M 5.56M 2024-09